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Healthcare services in KwaZulu-Natal (KZN), South 
Africa (SA) frequently experience shortages of blood 
products. This problem is common worldwide, but 
is particularly prevalent in Africa.[1] Blood shortages 
and the associated delays in supplying appropriate 
blood products impact negatively on patient care. Many emergency 
surgical interventions involve trauma and require blood immediately 
without the benefit of advance warning.[2] HIV prevalence has placed 
an additional burden on blood supplies by limiting the number of 
potential donors. Alternatives to traditional blood sources need to 
be found.[3]
One option is cell salvage (CS) and reinfusion of autologous blood. 
Misconceptions regarding the use of this system are common,[4] 
and few data exist relating to its use in the SA context. The 
benefit, feasibility and cost-effectiveness of intraoperative CS use has 
been questioned,[5] but extrapolation to the SA context is difficult, 
particularly as the sole published trial of CS in SA[2] included only 
patients with penetrating abdominal trauma. 
There are three main steps during intraoperative CS. Blood is 
suctioned from the surgical field using a double-lumen suction 
device, which adds heparinised saline to salvaged blood. The 
resulting mixture goes through a filter to a collection reservoir and 
then enters a spinning bowl where separation of red blood cells 
(RBCs) occurs through centrifugation. The RBC component is 
kept in the bowl while the lighter components move into the waste 
bag. Optical sensors detect a precise haematocrit (HCT). When the 
correct HCT is obtained, the machine begins to wash the salvaged 
blood. Normal saline is pumped into the spinning centrifuge system, 
passing through the heavier RBC component and out into the waste 
line displacing the residual waste products (anticoagulant, cell debris, 
free haemoglobin, plasma). The RBCs are added to normal saline to 
obtain an HCT between 50% and 60% and are then pumped into a bag 
ready for transfusion.[6,7] The disposable components for suctioning 
and collection of blood are supplied separately from the components 
that perform further processing into washed packed cells (Fig. 1). It 
is common practice to initially set up only the suctioning component 
(reservoir, suction line and anticoagulant) for blood collection and 
only set up the components for cell processing when enough blood 
has been collected to achieve a useful yield of processed cells. This 
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Collection Separation Washing Reinfusion
Partial setup: Suctioning and collection component
Suction: Haemonetics 5+ R205, Elite R205
Collection reservoir: Haemonetics 5+ R700, Elite R700
Total cost for partial setup per case: Haemonetics 5+ R905, Elite R905
Total cost of partial setup for the study period: R54 300 including VAT
Full setup: Suctioning and collection + processing components
Suction: Haemonetics 5+ R205, Elite R205
Collection reservoir: Haemonetics 5+ R700, Elite R700
Bowl: Haemonetics 5+ R895, Elite R1 077
Total cost of full setup per case: Haemonetics 5+ R1 800, Elite R1 982
Total cost of full setup for the study period: R151 747  including VAT
Fig. 1. Stages of cell salvage and the relevant setup required. 
RESEARCH
755  October 2013, Vol. 103, No. 10  SAMJ
strategy keeps costs down in the event of a less-than-expected yield 
of salvaged blood, while still allowing for easy availability of the Cell 
Saver during emergency procedures. The decision to use CS depends 
on the team managing the patient intraoperatively and is typically 
determined by the clinical situation.[8] 
Many different cases may be appropriate for CS. Indications 
for use should be individualised within the setting in which they 
are performed. Patient-specific factors as well as the local context, 
including financial and blood bank availability, influence the decision 
of when to use CS. International guidelines suggest that procedures 
in which CS can be useful include cardiac valve replacement, 
bypass grafting, major spinal surgery, thoracoabdominal aortic 
aneurysm repair and transplant surgery.[8] These types of procedures 
are rarely/never performed at the hospitals on which this study is 
based. However, both hospitals have a high burden of trauma, and 
obstetrics and gynaecology (O&G). These two disciplines have not 
traditionally been considered for CS owing to a perceived potential 
for complications.[4]
The Association of Anaesthetists of Great Britain and Ireland 
issued guidelines in 2009 that provide indications for intraoperative 
CS.[9] These include: the estimated loss of blood of >1 000 ml or >20% 
of the patient’s blood volume; low initial haemoglobin or patients that 
are at risk for bleeding; patients with unusual antibodies and blood 
types; and patients who decline transfusion of allogeneic blood.
Objective
To ascertain whether CS is beneficial, feasible and economical in 
our setting, with the anticipation that results would excite further 
studies and potentially change current practice and improve existing 
protocols.
Methods
The study was conducted at Grey’s and Edendale hospitals (in the 
Pietermaritzburg area of KZN). Grey’s Hospital is a referral hospital 
with 420 active beds, providing 20% regional and 80% tertiary 
services. Edendale is a regional and district level hospital with 900 
beds (480 regional and 420 district). Both hospitals cater to the needs 
of similar patient profiles with many trauma and obstetric cases. 
Moreover, patients are frequently transferred between these two 
hospitals, according to bed and resource availability. The doctors of 
the Pietermaritzburg Department of Anaesthesia, Critical Care and 
Pain Management (PDACCPM), who are responsible for the use 
of Cell Saver devices, represent a single staff pool who serve both 
hospitals. 
Each hospital had a Cell Saver 5+ autologous blood recovery system 
(Haemonetics, USA) at the start of the study, and in May 2013 Edendale 
acquired an additional Cell Saver Elite machine (Haemonetics, USA). 
The machines were purchased prior to or separate from the study.
A database was created to collate the cases where the Cell Saver 
was set up in the theatres and intensive care units over a 1-year 
period from July 2012 to June 2013. Data were collected by doctors 
in the PDACCPM using a simple questionnaire. Anaesthetists are 
responsible for the setup and operation of the Cell Saver device for all 
cases in these hospitals. Completing the questionnaire was voluntary 
and no patient details were recorded to retain patient confidentiality. 
The questionnaire was to be filled in whenever initial setup of the CS 
was performed irrespective of whether or not blood was processed or 
transfused. All patients in whom CS was considered were eligible for 
inclusion in the database, with no qualifying criteria. 
Data collection was via collection forms attached to each of 
the Cell Saver machines for easy access. Information collected 
included: date and time of the procedure, urgency of the case, type 
of procedure, discipline responsible for the patient, reasons for 
considering the case appropriate for Cell Saver use, reasons for not 
continuing to processing or transfusion (where applicable), and the 
amounts collected, processed and transfused.
Cost analyses were performed based on 2012/13 prices.[10,11] The 
cost of red cell concentrate (RCC) transfusions from the local SA 
National Blood Service (SANBS) blood bank increased in April 
2013 and cases from April to June 2013 were costed at the new 
price. Consumables that were actually used were costed at the 
relevant prices (Fig. 1). The CS costs were compared with the cost 
of the equivalent volume of RCC from the blood bank, excluding 
crossmatch. CS blood having an HCT of 50 - 60% and no platelets or 
clotting factors is similar to RCC. The CS blood was rounded to the 
nearest 300 ml to allow for comparison with the number of equivalent 
units that would otherwise have been ordered from SANBS. 
The purchase cost of the machine and its maintenance were considered. 
The 2013 purchase price for the Haemonetics Cell Saver 5+ is R200 000 
with costs of R1 500 per annum to service (A Rex, Product Manager, 
Belmont & Haemonetics Cell Saver, SA – personal communication). 
Allowing for depreciation over 5 years,[12] this equates to approximately 
R41 500 per year. The Haemonetics Cell Saver Elite costs R61 500 per 
year (A Rex, Product Manager, Belmont & Haemonetics Cell Saver, SA 
– personal communication). As the Haemonetics Cell Saver 5+ was used 
in all the cases, except two, this machine was used for cost analysis. These 
costs were added to the consumable costs.
The decision to set up the disposables and to continue to CS 
processing was made by anaesthetists based on clinical judgement 
and available protocols. The current PDACCPM guideline suggests 
a threshold of 800 ml of salvaged blood as being likely to produce a 
final yield of 1 unit (300 ml) of Cell Saver blood. Partial and full setup 
was recorded and used to accurately calculate the cost of the overall 
Cell Saver consumables for the study period.
Results
A total of 144 forms were completed. In 80/144 cases blood was 
generated from processing, equating to a total of 55 735 ml, which is 
the equivalent of 186 units of RCC from the SANBS. 
The number of units available after processing on a case-to-case 
basis is shown in Fig. 2. Approximately one-third of cases (32.5%) 
resulted in a single unit available for transfusion, with the remaining 
cases (67.5%) resulting in >1 unit available after processing. 
In 22 cases the Cell Saver was set up because there was no RCC 
available for the patient at the blood bank. Fifteen of these cases 
resulted in the patient receiving blood from CS with a total of 
8 143 ml being transfused. Of these patients, 10 received >1 unit from 



















Fig. 2. Blood units available after processing – per case.
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The majority of cases in the study were emergency cases (92%). Of 
these, 80 led to reinfusion of CS blood and 64 did not. There were 12 
elective cases, five of which resulted in transfusion. 
Fig. 3 shows the use of CS by discipline and summarises CS use and 
whether there was blood available for transfusion. Trauma and O&G 
accounted for the majority of the cases (88%). In 58% of trauma and 
59% of O&G cases there was ultimately Cell Saver-generated blood 
available for transfusion. There were insufficient cases from the other 
surgical disciplines for inclusion. Of the trauma cases, the instances of 
precordial stab wounds were more likely to continue onto processing 
(n=14/21) and the data suggest vascular trauma to be a potential 
area where CS may show particular benefit (6/7 cases of vascular 
trauma received blood from CS). Ruptured ectopic pregnancies most 
commonly went onto CS and transfusion (amounting to 32/42 in the 
obstetrics group). The other disciplines had too few cases to allow for 
comment although it was noted that all four total hip replacements 
ultimately received CS transfusions.
Regarding cases where only partial setup of the Cell Saver was 
completed, reasons for failure to proceed to CS transfusion are 
summarised in Fig. 4. Where an inadequate amount of blood was 
collected to warrant processing, there was an average of 473  ml 
collected, which is below the recommended minimum volume 
for processing in both the PDACCPM protocol and international 
recommendations.[9]
The consumables used for each case were considered and the 
associated costs were calculated (Table 1).
In the four cases where full setup was performed with production of 
CS RCC, but where no CS blood was transfused, the reasons were faecal 
contamination in two cases, technical difficulties in one and perceived 
inadequate clinical benefit in the fourth.
The costs of Cell Saver consumables and machine costs were 
compared with the cost of equivalent RCC purchased from SANBS 
(Fig. 5). 
Discussion
This study showed that intraoperative CS is feasible in the hospital 
settings of the hospitals surveyed. It was possible to run an effective 
CS service with existing staff who required short introductory 
training given by the company providing the equipment. In only 
2/144 cases did technical problems preclude CS processing. 
There is a justifiable concern that anaesthetic staff might be 
unable to perform their primary responsibilities if additionally 
required to operate the Cell Saver. However, only 10 - 15 minutes 
are required to set up the equipment to initiate collection, with 
an additional 10 minutes to process each unit of salvaged blood. 
Since anaesthetic staff are present throughout the procedure and 
have blood product and transfusion-related experience they are the 
logical choice for operating the CS systems when technologists are 
unavailable.[5] 
This study also showed that CS is potentially beneficial to the 
community: a significant amount of blood was saved, equating to 186 
units of RCC that were not required to be drawn from SANBS and 
were thus available for other patients.





Partial setup 60 54 300
Full setup (blood reinfused) 80 144 547
Full setup (available blood not reinfused) 4 7 200
Total consumable use for CS over study 
period
144 206 047
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Fig. 5. Blood bank costs compared with Cell Saver costs (RCC = red cell 
concentrate; ZAR = South African rand).
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There was also obvious benefit to the patients receiving CS blood 
as in 15 there was no banked blood available due to shortages at 
the blood bank. Ten of these patients received ≥2 units. CS blood is 
also available ‘immediately’, while there is frequently a delay in the 
delivery of blood from SANBS owing to shortages of supply.
In cases of critical anaemia even single unit transfusions may be of 
clinical benefit,[13] but the cost of the consumables exceeds that of one 
unit of RCC. Where ≥2 units have been salvaged, the cost of the CS 
consumables is less than the equivalent blood bank cost. 
We recognise that the current study was not designed to 
demonstrate clinical benefits or harms of CS use. While the study has 
identified the high utility of CS in trauma and O&G patients, it does 
not allow us to derive predictors of when CS is likely to be of greatest 
clinical benefit. This area requires further study. 
When considering the economic feasibility, the sole published SA 
study by Bowley et al.[2] found intraoperative CS to be cost neutral. 
This study, however, included only cases with penetrating abdominal 
wounds and the authors raised the concern that employment of 
technologists to perform CS would incur prohibitive costs.[3]
In our study, the costs of CS blood (consumables only) were 
lower than purchasing the equivalent RCC from SANBS. When 
machine depreciation costs are included, the Cell Saver blood became 
marginally more expensive than RCC. However, Cell Saver costs could 
be significantly reduced with more stringent guidelines as to when CS 
should be contemplated. Machine depreciation over five years is also 
conservative as the machines are reported by the manufacturer to last 
8 - 10 years. Even if CS use proves to be marginally more expensive 
than RCC, it still has the demonstrated ability to provide blood for 
patients when no other options are available.
In a large proportion of the cases there was inadequate blood 
collected to justify continuing with Cell Saver processing. This 
suggests that staff do not always correctly identify appropriate cases 
and do not predict potential blood loss correctly. However, in almost 
all cases staff did not proceed to the more expensive step when 
the inadequate blood loss was recognised, which ameliorated CS 
disposable costs. 
Our study highlighted the fact that the average yield from CS was 
substantially below those carried in international guidelines which 
recommend that 800 - 1 000  ml of collected blood should be the 
equivalent of one unit of washed RCC. In our study, a pooled average 
of 3 136  ml of blood was collected per case, yielding an average of 
only 697 ml for transfusion after processing. This might be explained 
by differences in the patient populations in that the majority of cases 
in our study were emergencies, where a lower initial HCT can be 
expected, while the international use is generally elective. Further 
study needs to be done to adequately identify these reasons and refine 
local protocols as appropriate. 
Conclusion
We have shown that using the Cell Saver is feasible without employing 
additional staff. The availability of CS blood was beneficial to both 
the community and the individual patient. Furthermore, using 
the Cell Saver was economical, with lower or comparable costs to 
equivalent SANBS RCC. These advantages are particularly relevant 
in the SA context where blood bank blood is frequently unavailable. 
References
1. Daramola AO, Banjo AA, Elesha SO. Maternal deaths in the Lagos University Teaching Hospital: A 
ten-year review (1989 - 1998). Niger Postgrad Med J 2004;11(4):274-278. 
2. Bowley DB, Barker PB, Boffard KD. Intra-operative blood salvage in penetrating abdominal trauma: A 
randomised, controlled trial. World J Surg 2006;30(6):1074-1080. [http://dx.doi.org/10.1007/s00268-
005-0466-2]
3. Osaro E, Charles AT. The challenges of meeting the blood transfusion requirements in Sub-Saharan 
Africa: The need for the development of alternatives to allogenic blood. J Blood Med 2011;2:7-21. 
[http://dx.doi.org/10.2147/JBM.S17194]
4. Esper S A, Waters J H. Intra-operative cell salvage: A fresh look at the indications and contraindications. 
Blood Transfus 2011;9(2):139-147. [http://dx.doi.org/10.2450/2011.0081-10]
5. Szpisjak DF, Potter PS, Capehart BP. Economic analysis of an intra-operative cell salvage service. 
Anesth Analg 2004;98(1):201-205. [http://dx.doi.org/10.1213/01.ANE.0000093231.53663.DD]
6. Allam J, Cox M, Yentis SM. Cell salvage in obstetrics. Int J Obstet Anaesth 2008;17(1):37-45. [http://
dx.doi.org/10.1016/j.ijoa.2007.08.001]
7. Amand T, Pincemail J, Blaffart F, Larbuisson R, Limet R, Defraigne JO. Levels of inflammatory 
markers in the blood processed by autotransfusion devices during cardiac surgery associated 
with cardiopulmonary bypass circuit. Perfusion 2002;17(2):117-123. [http://dx.doi.
org/10.1191/0267659102pf544oa]
8. Waters JH. Cell salvage indications and contraindications. Transfusion 2004;44(S2):40S-44S. [http://
dx.doi.org/10.1111/j.0041-1132.2004.04176.x]
9. The Association of Anaesthetists of Great Britain and Ireland. AAGBI Safety Guideline. Blood 
Transfusion and the Anaesthetist: Intra-operative Cell Salvage. London: AAGBI, 2009. http://www.
aagbi.org/sites/default/files/cell%20_salvage_2009_amended.pdf (accessed 1 June 2013).
10. SANBS. SANBS State Patients Price List 2012. http://www.sanbs.org.za/PDFDocuments/services/
Productspricelist/state%20patients%202012.pdf (accessed 23 August 2013).
11. SANBS. SANBS State Patients Price List 2013. http://www.sanbs.org.za/PDFDocuments/services/
Productspricelist/state%20patients%202013.pdf (accessed 23 August 2013).
12. American Hospital Association. Guidelines: Useful Life for Depreciation. http://www.aha.org/
research/rc/stat-studies/data-and-directories.shtml (accessed 1 June 2013).
13. Marshall C. Transfusion trigger: When to transfuse. Crit Care 2004;8(Suppl 2):S31-S33. [http://dx.doi.
org/10.1186/cc2846]
Accepted 20 August 2013.
